gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ABEOHealthcarePharmaceuticals

Abeona Therapeutics Inc. Common Stock (ABEO)

$4.22−0.71%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$4.25▼ 11.09% in range
Nov 3, 2025Low $4.17 · High $7.46Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Abeona Therapeutics closed at $4.22 on Nov 4, down 0.71%, within 1.2% of its 52-week closing low. Volume of 881.9K shares was 0.86× its 20-day average (close to normal).

Split-adjusted performance: -15.8% over one month, -29.8% over six months, -11.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $11.38M, up 2745.0% from a year earlier, with a net margin of -177.4%.

Short interest was 17.2M shares at the Oct 15 settlement, up 2.0% from the prior report (36.2% of float, 12.7 days to cover).

Market cap$241.3M57.2M shares
Revenue · quarter$11.4M+2745.0% YoY
Diluted EPS$-0.35−120.5% YoY
P/E · TTM—P/S 9.5×
Net margin-177.4%Gross 63.3%
Dividend yieldNone
52-week range4.17 – 7.46−43.4% from high
Volume881.9K0.86× 20-day avg
Volatility · 60d52.9%Annualised
Short % of float36.2%12.7 days to cover
Net cash$131.8MCash $146.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.3%1M −15.8%3M −38.8%6M −29.8%YTD −19.9%1Y −11.7%3Y +11.3%5Y −80.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum45
Revenue growth97
Net margin40
Value (low P/E)—
Size51

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short17.2M+2.0% vs prior
Days to cover12.7Settled Oct 15
% of float36.2%
Short vol. 10d57.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ABEOAbeona Therapeutics$4.22−0.71%−29.8%+2745.0%−177.4%—$241.3M
GLSIGreenwich LifeSciences$16.35+2.70%−29.1%———$240.0MCompare
LABStandard BioTools$0.6160+0.85%−36.4%−0.9%69.6%1.8$243.1MCompare
IMRXImmuneering$3.76+2.17%−27.6%———$243.5MCompare
LFCRLifecore Biomedical$6.44+0.31%+29.8%—−20.9%—$244.1MCompare
KRROKorro Bio$16.62+4.79%+24.6%−100.0%——$244.7MCompare
CAMPCAMP4 Therapeutics$3.74−2.35%−7.9%+18.8%−1884.8%—$234.7MCompare
VNDAVanda Pharmaceuticals$3.88+3.47%−47.8%+24.1%−32.3%—$234.6MCompare
SIGASIGA Technologies$3.15+1.29%−33.0%−49.5%30.4%—$226.3MCompare

News about Abeona Therapeutics

All news →
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOGlobeNewswire Inc. · Oct 6, 2026▼ NegativeAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Jul 1, 2026Neutral

Quick answers

What does Abeona Therapeutics do?
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases.
What is ABEO's market cap?
$241.32M, based on the Nov 4 close of $4.22.
Does Abeona Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ABEO is sold short?
17.2M shares, 36.2% of float, as of Oct 15, 2026.
What sector is ABEO in?
Healthcare, in the Pharmaceuticals industry.

About Abeona Therapeutics

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

HQ: Cleveland, OH226 employeesListed Sep 19, 1980abeonatherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology